UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)
September 28, 2007
 
BODISEN BIOTECH, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-32616
98-0381367
(State or other Jurisdiction
(Commission File Number)
(IRS Employer
of Incorporation)
  
Identification No.)
  
No. 1 Naguan Zhengjie
X’ian, Shaanxi 710068
People's Republic of China
(Address of Principal Executive Offices)
 
86-29-87895373
(Registrant’s Telephone Number, Including Area Code)
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 2.02 Results of Operations and Financial Condition and Item 7.01 Regulation FD Disclosure
 
    The following information is furnished under Item 2.02 - Results of Operations and Financial Condition and Item 7.01 - Regulation FD Disclosure:
 
    On September 28, 2007, Bodisen Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the first half of 2007. A copy of such press release is attached to this report as Exhibit 99.1 and is hereby incorporated herein by reference.
 
Item 9.01  Financial Statements and Exhibits
 
    (c) Exhibits.
 
    99.1 Press Release

 
2
 

SIGNATURES
 
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
 
     
    BODISEN BIOTECH, INC.
    (Registrant)
 
 		  
 		  
 
Date: September 28, 2007   /s/ Bo Chen
 
Bo Chen
  Chairman, Chief Executive Officer and   President
 
 
3